Sequenom (NASDAQ: SQNM) is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT. Sequenom's wholly owned subsidiarity, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, and the SensiGene RHD Fetal RHD genotyping test.

Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

NIPD Genetics Ltd., a subsidiary of Medicover AB, is a company headquartered in Nicosia, Cyprus, that operates as biotechnology company. The firm was founded in 2010 by Philippos C. Patsalis, who is currently the CEO of the firm. Medicover AB acquired NIPD Genetics Ltd. on January 18, 2022 for $50.32 million.

ARCEDI is a biotech company, develops technologies and methods for detecting and diagnosing rare cancer cells, as well as methods that will replace placenta biopsies with blood samples. ARCEDI provide a simpler, safer and accurate non-invasive prenatal diagnostic test to the pregnant women by analyzing the genome of the fetus using circulating fetal cells in maternal blood.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

LifeCodexx AG, part of Eurofins Scientific SE, is a German company located in Konstanz. The firm develops clinically validated molecular diagnostics.

Monaliza Medical Ltd. develops a genetic test platform enabling prenatal genetic screening in Transcervical Cell samples taken in the first trimester of pregnancy. It develops non-invasive prenatal screening and diagnostic tests for early detection of fetal abnormalities. The company was founded in 2004 and is headquartered in Ra'anana, Israel

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Invites Biocore is a biotechnology company that conducts experiments on biological organisms for pharmaceutical companies, contract research organizations (CROs), healthcare institutions, and research centers focused on pharmaceutical-related studies. Founded in 2001, Invites BioCore is a company offering Contract Research Organization (CRO) services specializing in genomic analysis and clinical trials. Their dedication spans the pre-clinical stage of drug development, genetic testing for various life stages, in vitro diagnostic production, and cold chain bio-logistics services.

Vitatex, Inc. focuses on advance personalized medicine with tests of invasive circulating tumor cells. It develops proprietary diagnostic tests that can be run on blood samples, collected by standard current methods, to improve cancer treatment decisions and select effective therapies for recurrence and metastatic diseases. The company was founded by Wen-Tien Chen and is headquartered in Stony Brook, NY.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.